Table 3 Patterns of antihypertensive and nephroprotective agents use for a group of patients with type 2 diabetes mellitus and chronic kidney disease in Colombia

Angiotensin II receptor blocker

67.2

49.2

 Losartan

53.4

97.5 ± 37.6

1.9

48.6

 Losartan/Hydrochlorothiazide

6.6

99.5 / 22.7

2

48.6

 Irbesartan

4.1

261.5 ± 73.6

1.7

60.2

 Valsartan

3.8

225.8 ± 89.4

2.8

45.9

 Valsartan/Hydrochlorothiazide/Amlodipine

1.5

216.3 / 16.1 / 8.9

2.7

45.9

 Irbesartan/Amlodipine

1.3

280.5 / 8.6

1.9

 Telmisartan

1.1

87.3 ± 29.1

2.2

49

 Telmisartan/Amlodipine

0.6

90.3 / 9.1

2.3

 Candesartan

0.5

21.9 ± 11.1

2.7

56.9

 Irbesartan/Hydrochlorothiazide

0.4

280.5 / 18.8

1.9

 Valsartan/Hydrochlorothiazide

0.3

216.3 / 16.1

2.7

 Losartan/Amlodipine

0.2

99.5 / 7.3

2

 Olmesartan

0.2

38.2 ± 9.4

1.9

55.6

 Telmisartan/Hydrochlorothiazide

0.1

90.3 / 17.2

2.3

 Olmesartan/Amlodipine

0.1

38.2 / 8.7

1.9

 Eprosartan

0.1

600 ± NA

1

50

 Olmesartan/Hydrochlorothiazide

0.04

38.2 / 23.2

1.9

 Candesartan/Hydrochlorothiazide

0.03

32 / 17.5

4

Angiotensin converting enzyme

15.8

56.6

 Enalapril

15

21.6 ± 15.2

2.1

57.3

 Captopril

0.7

71.6 ± 31.9

1.4

40.4

 Lisinopril

0.07

21.7 ± 9.4

2.1

33.3

 Perindopril/Indapamide

0.04

8.88 / 7.5

2.2

62.5

 Perindopril/Amlodipine

0.06

8.88 / 2.2

2.2

62.5

 Quinapril

0.01

30 ± NA

2

100

 Perindopril

0.01

8.88 ± NA

2.2

62.5

Mineralocorticoid receptor antagonist

10.9

58.4

 Spironolactone

10.7

27.5 ± 13.6

0.36

58.3

 Eplerenone

0.2

35.4 ± 14.3

0.7

71.4

Calcium channel blockers

 Amlodipine

54.9

6.3 ± 2.2

1.26

50.9

 Nifedipine (retard)

6.6

34.4 ± 10.6

1.14

47.3

 Verapamil

3.2

175.7 ± 56.8

0.24

36.1

β-blockers

 Metoprolol

15.5

86.8 ± 35.7

0.58

49.2

 Carvedilol

14

21.6 ± 13.4

0.57

58.1

 Nebivolol

0.2

4.6 ± 2.6

0.92

53.6

 Propranolol

0.6

56.7 ± 26.5

0.35

50.9